Geoffrey Meacham JPMorgan
Geoffrey Porges Sanford C. Bernstein
Mark Schoenebaum, who joined Deutsche Bank Securities in June, after his former firm, Bear, Stearns & Co., was absorbed by JPMorgan Securities, remains “one of the most accessible, friendly and knowledgeable analysts in the sector,” according to one hedge fund manager. Schoenebaum, 35, also remains No. 1 for a fourth consecutive year. He initiated coverage of Genentech in June with a buy rating, at $74.36, on the belief that Swiss drugmaker Roche Holding, which owns a controlling interest in the San Francisco–based cancer treatment developer, would be unsuccessful in its attempts to acquire the remaining shares. He was right. By mid-September, Genentech’s stock had shot up to $96.56 — a healthy 29.9 percent gain that outperformed the sector by 15.3 percentage points. Geoffrey Meacham of JPMorgan Securities leaps from runner-up to second place, thanks in part to what clients call “a great sense for how much a potential drug is really worth” and “fast, insightful reactions.” In December, Meacham highlighted his long-standing buy recommendation on Celgene Corp., reasoning that rising demand in Europe for the Summit, New Jersey–based company’s myeloma treatment drug Revlimid would more than offset competitive threats in the U.S. By mid-September the stock had soared 44.7 percent. Although he slips one notch to third, Geoffrey Porges of Sanford C. Bernstein & Co. continues to impress investors with what one backer calls “in-depth, exquisitely thoughtful work.” In May, Porges upgraded Cambridge, Massachusetts–based Genzyme Corp. to buy, at $68.01, on its growing pipeline. By mid-September the stock had risen 17.4 percent, to $79.85.